Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Minocin MR 100 mg Modified Release Capsules

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Minocycline hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Minocycline hydrochloride

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Minocycline, the active ingredient in MINOCIN MR, is a tetracycline antibiotic used in the treatment of acne. Acne results from clogging of skin pores. In its mildest form this causes whiteheads and blackheads. If these become infected, spots appear. MINOCIN MR reduces the infection and allows the spots to heal.

What you need to know before you take it

e MINOCIN MR Do not take these capsules if any of the following apply to you unless you have told your doctor or pharmacist:

  • you have had an allergic reaction to any tetracycline antibiotic in the past (e.g. oxytetracycline, tetracycline, doxycycline or minocycline), or any of the components of MINOCIN MR;
  • you are pregnant, breastfeeding or trying for a baby;
  • the person that the medicine has been prescribed for is under the age of 12;
  • you have kidney disease; Warning and precautions: Tell your doctor or pharmacist if:
  • you are taking any of the following: anticoagulants e.g. warfarin; penicillin antibiotics e.g. amoxicillin; isotretinoin (or other retinoids or retinol); quinapril, ergotamine, methysergide, indigestion remedies, vitamins or any preparations containing iron, calcium, aluminium, magnesium, bismuth or zinc salts; diuretics, lithium containing products.
  • you are taking any other medicines including those that you have bought without a prescription;
  • you are taking preparations containing iron, calcium, aluminium, magnesium, bismuth or zinc salts which can prevent MINOCIN MR from working effectively when taken at the same time. It is recommended that any indigestion remedies, vitamins or other supplements containing these are taken at least 3 hours before or after your dose of MINOCIN MR;
  • you have a condition called systemic lupus erythematosus (SLE) or myasthenia gravis;
  • you have liver disease.

MINOCIN MR may affect some medical tests. If you visit a hospital or clinic for any medicinal tests you should tell your doctor concerned you are taking MINOCIN MR. Taking other medicines If you take a contraceptive pill and get diarrhoea or sickness or bleed when you don't expect to, your pill may not work (please see "4. Possible Side Effects"). Taking MINOCIN MR with food and drink It is recommended that whilst taking MINOCIN MR alcohol consumption should remain within the Government's recommended limits.

How to take it

MINOCIN MR Always take your capsules exactly as your doctor tells you to. This information will also be on the pharmacist's label. If you are not sure how to take your capsules your pharmacist will be able to help you. The usual dose is one capsule every day. For elderly patients, your doctor will advise if any dosage reduction is required. MINOCIN MR should be taken at the same time(s) each day. MINOCIN MR should be swallowed whole with a drink of water. The capsules should be taken while you are sitting or standing. They should not be sucked or chewed. It does not matter whether you take MINOCIN MR on an empty stomach or after food. Do not remove a capsule from the pack until you are due to take it. The container protects the capsules from moisture, which may spoil them. Never take more capsules than the doctor has told you to, it will not help you get better any faster and it could be harmful to you. Acne responds quite slowly to antibiotics and it may be several weeks before you see any improvement in your acne and even longer before the full benefits are seen. For this reason it is important to finish taking all of the capsules prescribed for you by your doctor and return to see him/her when you have been asked to do so. If, however, your acne has not improved after a treatment period of six months, you should return to your doctor to have your treatment reviewed. If your doctor decides to continue your treatment with MINOCIN MR for longer than 6 months, your doctor should ask to see you on a regular basis, usually once every 3 months, to examine you for any possible side effects related to the liver or unusual pigmentation or a condition called Systemic Lupus Erythematosus (SLE) which can include pain or stiffness of joints, rash or fever. Your doctor will also monitor your blood and renal function during therapy. If You Take More MINOCIN MR Than You Should If you have accidentally taken an overdose of MINOCIN MR, that is more capsules than the doctor has told you to take, you should get medical help immediately, either by calling your doctor or by going to the nearest hospital accident and emergency department. Always take the labelled medicine container with you, whether there are any MINOCIN MR capsules left or not. If You Forget To Take MINOCIN MR If you do miss a dose you should take it as soon as possible. This will help to keep a constant amount of medicine in the blood. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take a double dose.

Possible side effects

Like all medicines MINOCIN MR may cause side effects although not everybody gets them. Most people do not get side effects with this medicine. Serious side effects Get medical attention IMMEDIATELY if you experience any of the following;

  • sudden onset of swelling of your throat and tongue, difficulty breathing or breathing very fast, difficulty swallowing, tightness in your throat, wheezing, coughing or noisy breathing, feeling faint, dizzy or fainting. You may also develop a rash that's swollen, raised or itchy. These are symptoms of a life threatening allergic reaction (anaphylaxis/anaphylactoid reaction);
  • a skin rash made up of circular patches that are darker in the middle and lighter around the outside, with painful blisters on your mouth, throat, genitals or eyes (Stevens-Johnson syndrome) or a red, scaly rash with skin peeling (exfoliative dermatitis). You may also feel generally unwell with flu-like symptoms like a fever, sore throat and joint pain with these skin reactions;
  • Inflammation of the heart muscles, symptoms include- flu like symptoms, chest pain or tightness of the chest, shortness of breath, irregular heartbeat, feeling lightheaded (myocarditis);
  • Inflammation of lining around your heart, symptoms include- flu like symptoms, chest pain that is felt on the left hand side of the chest or behind your breast bone that gets worst when coughing, swallowing or taking a deep breath and gets better when leaning forward (pericarditis);
  • when your laboratory results shows a high number of eosinophils (a type of white blood cell that supports your immune system), symptoms include but not limited to weight loss, fever, night sweat, swelling and confusion (eosinophilia);
  • Inflammation of the liver, muscle and joint pain, fever, flu like symptoms, tummy pain, dark urine, pale grey coloured poo, yellowing of the eye and skin and itchy skin (hepatitis);
  • Inflammation of the kidney which can cause swollen ankles, blood in the urine, decrease in number of times you wanting to urinate or high blood pressure (nephritis);
  • Inflammation of the lung tissues which causes breathlessness, cough and raised temperature (pneumonitis);
  • Fever and lymphadenopathy (swollen or enlarged lymph nodes) may be present;
  • joint pain (arthralgia);
  • joint stiffness or joint swelling, extreme tiredness and rash over your nose and cheeks accompanied by swollen glands (systemic lupus erythematosus);
  • Hyperpigmentation of various body sites (e.g. skins, nails, teeth, oral mucosa, bones, thyroid, eyes (including sclera and conjunctiva), breast milk, lacrimal secretions and perspiration); Other side effects The following effects that can occur are usually mild, rare or very rare but if you experience any symptoms which are severe, persist or worry you, contact your doctor or pharmacist: Common (may affect up to 1 in 10 people)
  • Dizziness (light-headedness); Uncommon (may affect up to 1 in 100 people) •Fever; Rare (may affect up to 1 in 1,000 people)
  • skin problems such as rashes most commonly due to increased sensitivity of the skin to sunlight, itching, redness, scaling or blistering. You should avoid direct exposure to sunlight or artificial light. If you experience skin discomfort then stop taking your tablets and seek advice from your doctor;
  • loss of hair (alopecia);
  • severe skin rashes, as they may be life threatening;
  • Headache, with blurred or double vision or loss of vision;
  • feeling of dizziness or "spinning" (vertigo);
  • build up of pressure around the brain (intracranial hypertension);
  • Cough.
  • shortness of breath (dyspnoea);
  • hearing problems such as ringing in the ears (tinnitus). Make sure you know how you react to this medicine before you drive, use machines or do anything else that could be dangerous if you are dizzy or not alert;
  • stomach upsets, diarrhoea, sickness, loss of appetite or sore mouth. If you take a contraceptive pill and get diarrhoea or sickness or bleed when you don't expect to, your "pill" may not work. You should use a different or additional means of birth control (e.g. a condom or diaphragm/cap) to ensure you are protected. Read the leaflet that came with your "pill" •Vomiting;
  • increased liver enzymes (liver problems);
  • increased serum urea (kidney problems);
  • Swelling in legs, ankles, and around the eyes, feeling confused or fatigued, and too little urine leaving the body (acute kidney failure);
  • Abnormally low levels of white blood cells, resulting in an increase in infections (neutropenia);
  • reduction in blood platelets, which increases risk of bleeding or bruising (thrombocytopenia);
  • swollen, stiff or painful joints or muscle pain. Tender, bruise like swellings of the shins;
  • pain in the abdomen, pale stools or difficulty passing urine;
  • sudden unexplained fever or sore throat, extreme tiredness, unexplained bruising or bleeding;
  • Numbness, tingling feelings (like pins and needles) in the hands and feet;
  • eating disorder causing loss of weight (anorexia);
  • difficulty breathing or chest pain (myocarditis); Very rare (may affect 1 in 10,000 people)
  • abnormal thyroid function, including brown-black discoloration of the thyroid;
  • reduction in red blood cells which can make the skin pale or yellow and cause weakness or breathlessness (anaemia);
  • Swelling of the pancreas which can leads to pain in the centre of your abdomen, nausea and fever (pancreatitis)
  • red patches on the skin, white patches in the mouth or itching around the anus or vagina which may be accompanied by vaginal discharge. Vaginal inflammation which may be accompanied by pain on urinating;
  • build up of fluid in the brain or swelling of the brain due to increased pressure (bulging fontanelle);
  • difficulty in breathing or wheezing (bronchospasm);
  • infiltration of eosinophils, a type of white blood cells, into the lungs causing breathing difficulties, chest tightness, pain, fever, cough and wheezing (pulmonary eosinophilia);
  • Heartburn or difficulty in swallowing, lower abdominal pain or blood and mucous in stools (oesophageal ulceration);
  • teeth defect where the outer lining of the teeth is missing or thinned (enamel hypoplasis);
  • inflammation of the digestive tract due to a bacterial infection (enterocolitis);
  • Inflammation of the oesophagus (oesophagitis);
  • Inflammation of the tongue (glossitis);
  • a severe form of colitis which affects the lining of the colon causing abdominal discomfort and diarrhoea (pseudomembranous colitis);
  • oral cavity discoloration (including tongue, lip and gum);
  • loss of appetite, feeling sick, itchy skin, vomiting blood, build up of fluid in the legs and abdomen (liver failure or cirrhosis);
  • serious liver problems (e.g. hepatic cholestasis and hyperbilirubinemia);
  • yellowing of the skin or whites of the eyes (jaundice);
  • a worsening or development of symptoms of SLE (systemic lupus erythematosus) or a worsening of the symptoms of myasthenia gravis (weakness of muscles);
  • Inflammation of blood vessels, often with skin rash;
  • Swelling and redness of the tongue, inside of the mouth, or around the eyes (angioedema);
  • Inflammation of the blood vessels of all sizes affecting both veins and arteries, symptom includes fever, fatigue, joint pain, purple skin discolorations, weight loss and numbness/tingling of arms and legs (vasculitis);
  • redness or swelling of the penis (balanitis);
  • discolouration of secretions such as sweat or tears; Not known (frequency cannot be estimated from the available data)
  • uncontrollable shaking of the muscles (convulsions);
  • Sedation.
  • inflammation of the liver that occurs when your body's immune system turns against your liver (autoimmune hepatitis);
  • a form of relapsing vasculitis affecting medium size blood vessels, symptoms include weight loss, muscle and joint pain, skin rashes and ulcers and numbness/tingling of arms and legs (polyarteritis nodosa);
  • severe reduction in the number of white blood cells which makes infections more likely (agranulocytosis); Contact your doctor if you notice any staining of your skin, teeth (including adult teeth), tongue, lips, gums or nails so that your treatment can be reviewed. Slight blue/black/grey colour staining of the skin, teeth, nails, inside of the mouth, eyes, tears, breast milk or sweat has been reported. Staining may appear at any time during MINOCIN MR therapy but is more common during long-term treatment. Any blue/black/grey staining of the skin or mouth usually disappears a few months after MINOCINMR is stopped. Staining in the other parts of the body, although less common, may persist. A persistent muddy-brown skin stain, particularly in sun exposed areas of the skin, has also been reported. Inform your doctor without delay if you notice any staining so that your treatment can be reviewed. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

MINOCIN MR Keep out of the reach and sight of children Do not use MINOCIN MR after the expiry date. This date is printed on the pack. Do not store above 25°C Blisters: Store in the original container Keep the container in the outer carton Bottles: Keep the container tightly closed. Store in the original container.

If your doctor decides to stop your treatment you should return any capsules that are left to your pharmacist for disposal. Medicines should not be put down the sink or toilet or in the bin.

Contents of the pack and other information

What MINOCIN MR Contains Each capsule contains 100mg of the active ingredient minocycline hydrochloride. Minocycline is one of a group of antibiotics called the tetracyclines. The capsule body contains titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172) and gelatin. The capsule cap ingredients are iron oxide black (E172) and those listed for the capsule body. Other ingredients which are added so that MINOCIN MR can be swallowed easily include microcrystalline cellulose, croscarmellose sodium, hypromellose phthalate 50, hypromellose (E464) and light liquid paraffin. What MINOCIN MR Looks Like and Contents of the Pack MINOCIN MR is a modified release capsule and is available in one strength and a variety of pack sizes and presentations. MINOCIN MR is licensed for the following pack sizes: (i) Blister packs of 2, 49 and 56. (ii) Bottles of 100. MINOCIN MR is currently supplied in pack sizes of 56. MINOCIN MR is a two piece, hard shell, size 2 capsules with an orange opaque body and a brown opaque cap containing a mixture of off-white and coloured (yellow, green, brown/black) spherical pellets. Marketing Authorisation Holder: Viatris Products Limited, Station Close, Potters Bar, EN6 1TL, United Kingdom.

Manufacturer: Mylan Hungary Kft., Mylan utca 1., Komárom, 2900, Hungary

This leaflet was last revised in 10/2025. For any further information about this medicine, please contact the Marketing Authorisation Holder.

Frequently asked questions about Minocin MR 100 mg Modified Release Capsules

How do I take Minocin MR 100 mg Modified Release Capsules?

Minocin MR 100 mg Modified Release Capsules comes as capsule containing 100mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Minocin MR 100 mg Modified Release Capsules?

The active substance in Minocin MR 100 mg Modified Release Capsules is minocycline hydrochloride.

Are there equivalent medicines to Minocin MR 100 mg Modified Release Capsules?

Medicines with the same active substance, strength and form include: Acnamino MR 100mg Capsules. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Minocin MR 100 mg Modified Release Capsules, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Minocin MR 100 mg Modified Release Capsules without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Minocycline hydrochloride (2 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

MINOCIN MR Capsules are indicated for the treatment of acne.

4.2. Posology and method of administration

Posology

Adults

One 100mg capsule every 24 hours

Paediatric Population

Children over 12 years: One 100mg capsule every 24 hours

Children under 12 years: Minocycline is not recommended

Elderly

No special dosing requirement

Method of Administration:

To reduce the risk of oesophageal irritation and ulceration, the capsules should be swallowed whole with plenty of fluid, while sitting or standing. Unlike earlier tetracyclines, absorption of minocycline is not significantly impaired by food or moderate amounts of milk.

Treatment of acne should be continued for a minimum of 6 weeks, and where possible limited to a maximum of six months. If, after six months, there is no satisfactory response Minocin MR should be discontinued and other therapies considered.

If Minocin MR is to be continued for longer than six months, patients should be monitored (including laboratory investigations) at least three monthly thereafter for signs and symptoms of hepatitis or systemic lupus erythematosus (SLE) or unusual pigmentation. (see Special Warnings and Precautions)

4.3. Contraindications

Use of minocycline is contraindicated in the following:

• Hypersensitivity to the active substance minocycline, other tetracyclines or to any of the excipients.

• Pregnancy and lactation.

• Children under the age of 12 years.

• Complete renal failure.

4.4. Special warnings and precautions for use

Rare, anaphylaxis/anaphylactoid reactions including shock and fatalities have been associated with the administration of Minocin MR ( See section 4.8 Undesirable effects).

Minocin MR should be used with caution in patients with hepatic dysfunction and in conjunction with alcohol and other hepatotoxic drugs. It is recommended that alcohol consumption should remain within the Government's recommended limits.

Rare cases of auto-immune hepatotoxicity and isolated cases of systemic lupus erythematosus (SLE) and also exacerbation of pre-existing SLE have been reported. If patients develop signs or symptoms of SLE or hepatotoxicity, or suffer exacerbation of pre-existing SLE, minocycline should be discontinued.

Other rare, serious events have occurred with Minocin MR including Stevens-Johnson Syndrome and toxic epidermal necrolysis. (See section 4.8 Undesirable effects). Minocin MR should be discontinued if either of these serious skin reactions is suspected.

Clinical studies have shown that there is no significant drug accumulation in patients with renal impairment when they are treated with Minocin MR in the recommended doses. In cases of severe renal insufficiency, reduction of dosage and monitoring of renal function may be required. The anti-anabolic action of the tetracyclines may cause an increase in serum urea. In patients with significantly impaired renal function, higher serum levels of tetracyclines may lead to uraemia, hyperphosphataemia and acidosis. If renal impairment exists, even usual oral and parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity.

Caution is advised in patients with myasthenia gravis as tetracyclines can cause weak neuromuscular blockade.

Cross-resistance between tetracyclines may develop in micro-organisms and cross-sensitisation in patients. Minocin MR should be discontinued if there are signs/symptoms of overgrowth of resistant organisms, e.g. enteritis, glossitis, stomatitis, vaginitis, pruritus ani or Staphylococcal enteritis.

Patients taking oral contraceptives should be warned that if diarrhoea or breakthrough bleeding occur there is a possibility of contraceptive failure.

Minocycline may cause hyperpigmentation at various body sites (see Administration and 4.8 Undesirable Effects). Hyperpigmentation may present regardless of dose or duration of therapy but develops more commonly during long term treatment. Patients should be advised to report any unusual pigmentation without delay and Minocin MR should be discontinued.

If a photosensitivity reaction occurs, patients should be warned to avoid direct exposure to natural or artificial light and to discontinue therapy at the first signs of skin discomfort.

As with other tetracyclines, bulging fontanelleles in infants and benign intracranial hypertension in juveniles and adults have been reported. Presenting features were headache and visual disturbances including blurring of vision, scotoma and diplopia. Permanent vision loss has been reported.

Treatment should cease if evidence of raised intracranial pressure develops.

Elderly:

Dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Paediatric population:

The use of tetracyclines during tooth development in children under the age of 12 years may cause permanent discolouration. Enamel hypoplasia has also been reported.

Laboratory monitoring:

Periodic laboratory evaluations of organ system function, including haematopoietic, renal and hepatic should be conducted.

4.5. Interaction with other medicinal products and other forms of interaction

Tetracyclines depress plasma prothrombin activity and reduced doses of concomitant anticoagulants may be necessary.

Diuretics may aggravate nephrotoxicity by volume depletion.

Bacteriostatic drugs may interfere with the bactericidal action of penicillin. Avoid giving tetracycline-class drugs in conjunction with penicillin. Absorption of Minocin MR is impaired by the concomitant administration of antacids, iron, calcium, magnesium, aluminium bismuth and zinc salts (interactions with specific salts, antacids, bismuth containing ulcer – healing drugs, quinapril which contains a magnesium carbonate excipient). It is recommended that any indigestion remedies, vitamins, or other supplements containing these salts are taken at least 3 hours before or after a dose of Minocin MR. Unlike earlier tetracyclines, absorption of Minocin MR is not significantly impaired by food or moderate amounts of milk.

The concomitant use of tetracyclines may reduce the efficacy of oral contraceptives.

Administration of isotretinoin should be avoided shortly before, during and shortly after minocycline therapy. Each drug alone has been associated with pseudotumor cerebri (benign intracranial hypertension) (see 4.4 Special warnings and precautions).

Interference with laboratory and other diagnostic tests:

False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

4.6. Fertility, pregnancy and lactation

Use in pregnancy:

Minocycline is contraindicated during pregnancy as it can cause fetal harm.

Results of animal studies indicate that tetracyclines cross the placenta, are found in foetal tissues and can have toxic effects on the developing foetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. Minocin MR therefore, should not be used in pregnancy unless considered essential.

In humans, minocycline like other tetracycline-class antibiotics, crosses the placenta and may cause foetal harm when administered to a pregnant woman. In addition, there have been post marketing reports of congenital abnormalities including limb reduction. If Minocin MR is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to the foetus.

The use of drugs of the tetracycline class during tooth development (last half of pregnancy) may cause permanent discolouration of the teeth (yellow-grey-brown). This adverse reaction is more common during long term use of the drugs but has been observed following repeated short term courses. Enamel hypoplasia has also been reported.

Tetracyclines administered during the last trimester form a stable calcium complex throughout the human skeleton. A decrease in fibula growth rate has been observed in premature human infants given oral tetracyclines in doses up to 25mg/kg every 6 hours. Changes in fibula growth rate were shown to be reversible when the drug was discontinued.

Use in lactation:

Tetracyclines have been found in the milk of lactating women who are taking a drug in this class. Permanent tooth discolouration may occur in the developing infant and enamel hypoplasia has been reported.

4.7. Effects on ability to drive and use machines

Headache, light-headedness, dizziness, tinnitus and vertigo (more common in women) and, rarely, impaired hearing have occurred with Minocin MR. Patients should be warned about the possible hazards of driving or operating machinery during treatment. These symptoms may disappear during therapy and usually disappear when the drug is discontinued.

4.8. Undesirable effects

The assessment of side effects is based on the following frequency information:

Very common (≥ 1/10)

Common: ((≥1/100 to <1/10)

Uncommon: (≥1/1 000 to <1/100)

Rare: (≥1/10 000 to <1/1 000)

Very Rare: (<1/10 000)

Not known (cannot be determined based on available data).

System Organ Class

Frequency

Adverse Reaction

Infections and Infestations

Very Rare

Oral and anogenital candidiasis, vulvovaginitis.

Blood and Lymphatic System Disorders

Rare

Eosinophilia, leucopoenia, neutropenia, thrombocytopenia

Very Rare

Haemolytic anaemia, pancytopenia.

Not known

Agranulocytosis

Immune System Disorders

Rare

Anaphylaxis/anaphylactoid reaction (including shock and fatalities)

Not Known

Hypersensitivity, pulmonary infiltrates, anaphylactoid purpura, Polyarteritis nodosa.

Endocrine Disorders

Very Rare

Abnormal thyroid function, brown-black discolouration of the thyroid

Metabolism and Nutrition Disorders

Rare

Anorexia

Nervous System Disorders

Common

Dizziness (light-headedness)

Rare

Headache, hypaesthesia, paraesthesia, intracranial hypertension, vertigo

Very Rare

Bulging fontanelle

Not Known

Convulsions, sedation

Ear and Labyrinth Disorders

Rare

Impaired hearing, tinnitus

Cardiac Disorders

Rare

Myocarditis, Pericarditis

Respiratory, Thoracic and Mediastinal Disorders

Rare

Cough, dyspnoea

Very Rare

Bronchospasm, exacerbation of asthma, pulmonary eosinophilia

Not Known

Pneumonitis

Gastrointestinal Disorders

Rare

Diarrhoea, nausea, stomatitis, discolouration of teeth (including adult tooth discolouration), vomiting

Very Rare

Dyspepsia, dysphagia, enamel hypoplasis, enterocolitis, oesophagitis, oesophageal ulceration, glossitis, pancreatitis, pseudomembranous colitis There are also reports of: Oral cavity discolouration (including tongue, lip and gum)

Hepatobiliary Disorders

Rare

Increased liver enzymes, hepatitis, autoimmune toxicity

Very Rare

Hepatic cholestatis, hepatic failure (including fatalities), hyperbilirubinaemia, jaundice

Not Known

Autoimmune hepatitis

Skin and Subcutaneous Tissue Disorders

Rare

Alopecia, erythema multiforme, erythema nodosum, fixed drug eruption, hyperpigmentation of skin, photosensitivity, pruritus, rash, urticaria

Very Rare

Angioedema, exfoliative dermatitis, hyperpigmentation of nails, Stevens-Johnson Syndrome, toxic epidermal necrolysis, vasculitis.

Musculoskeletal, Connective Tissue and Bone Disorders

Rare

Arthralgia, lupus-like syndrome, myalgia

Very Rare

Arthritis, bone discolouration, cases of or exacerbation of systemic lupus erythematosus (SLE), joint stiffness, joint swelling

Renal and Urinary Disorders

Rare

Increase serum urea, Acute renal failure, interstitial nephritis.

Reproductive System and Breast Disorders

Very Rare

Balanitis

General Disorders and Administration Site Conditions

Uncommon

Fever

Very Rare

Discolouration of secretions

The following syndromes have been reported. In some cases involving these syndromes, death has been reported. As with other serious adverse reactions, if any of these syndromes are recognised, the drug should be discontinued immediately:

• Hypersensitivity syndrome consisting of cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, pericarditis.

• Fever and lymphadenopathy may be present.

• Lupus-like syndrome consisting of positive antinuclear antibody, arthralgia, arthritis, joint stiffness or joint swelling, and one or more of the following: fever, myalgia, hepatitis, rash, vasculitis.

• Serum sickness-like syndrome consisting fever, urticaria or rash, and arthralgia, arthritis,joint stiffness or joint swelling. Eosinophilia may be present.

• Hyperpigmentation of various body sites including the skin, nails, teeth, oral mucosa, bones, thyroid, eyes (including sclera and conjunctiva), breast milk, lacrimal secretions and perspiration has been reported.

This blue/black/grey or muddy-brown discolouration may be localised or diffuse. The most frequently reported site is in the skin. Pigmentation is often reversible on discontinuation of the drug, although it may take several months or may persist in some cases. The generalised muddy-brown skin pigmentation may persist, particularly in areas exposed to the sun.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Dizziness, nausea and vomiting are the adverse effects most commonly seen with overdose. There is no specific antidote. In cases of overdose, discontinue medication, treat symptomatically with appropriate supportive measures. Minocycline is not removed in significant quantities by haemodialysis or peritoneal dialysis.

💬 Ask about this leaflet

Ask anything about Minocin MR 100 mg Modified Release Capsules. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Medicines containing Minocycline hydrochloride

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →